Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 6Crohn Disease 4Colitis, Ulcerative 4Colitis 4Carcinoma, Non-Small-Cell Lung 4Lung Neoplasms 3Inflammatory Bowel Diseases 3Arthritis, Rheumatoid 3Urogenital Neoplasms 2Inflammation 2Hematologic Neoplasms 2Graft vs Host Disease 2Fatigue 2Depressive Disorder, Major 2Depression 2Cachexia 2Anorexia 2Vasculitis 1Takayasu Arteritis 1Syndrome 1Stroke 1Stevens-Johnson Syndrome 1Skin Neoplasms 1Recurrence 1Rare Diseases 1Pemphigoid, Benign Mucous Membrane 1Pancreatic Neoplasms 1Lymphoma 1Kidney Transplantation 1Hypertension 1

Interventions

Amifostine 19Cisplatin 15Radiotherapy 13Etoposide 10Cyclophosphamide 9Carboplatin 8Paclitaxel 7Filgrastim 7Drug Therapy 5Cytarabine 5apatinib 4sodium thiosulfate 3Methylprednisolone 3Methotrexate 3Gemcitabine 3Docetaxel 3sargramostim 2pegfilgrastim 2etoposide phosphate 2camrelizumab 2Vincristine 2Pyridoxine 2Peripheral Blood Stem Cell Transplantation 2Nivolumab 2Mitoxantrone 2Melphalan 2Irinotecan 2Ifosfamide 2Fibroblast Growth Factor 7 2Epoetin Alfa 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Drug-Related Side Effects and Adverse Reactions × Infliximab × Clear all
NCT04305145 2026-01-29

Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis

Massachusetts General Hospital

Phase 2 Active not recruiting
42 enrolled
Dermatologic

Colitis, Melanoma, Skin Neoplasms, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡